论文部分内容阅读
目的:探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)的4个受体DR4、DR5、DcR1、DcR2在喉癌中的表达及意义。方法:应用免疫组织化学方法,检测68例喉鳞状细胞癌及40例正常喉黏膜中TRAIL的受体DR4、DR5、DcR1、DcR2的表达情况。结果:在喉癌组织及喉正常黏膜中均表达TRAIL的4个受体,其中死亡受体DR4、DR5在喉癌组织及正常喉黏膜中均呈高表达,均差异无统计学意义(均P>0.05),而诱骗受体DcR1、DcR2在正常喉黏膜中表达较高,在喉癌组织中则表达低,均差异有统计学意义(均P<0.05)。喉癌组织分化程度越高,则DR5表达越低,DcR2的表达越高,差异有统计学意义(P<0.05)。而各个临床分期的癌组织中,4个受体的表达均无明显差异(均P>0.05)。结论:喉癌组织中普遍存在着TRAIL受体的表达,并存在着受体类型表达的差异。TRAIL抑制肿瘤作用可能与基因受体DcR1、DcR2在不同组织的分布不同有关。TRAIL基因受体DR5、DcR2可能在不同病理分期喉癌的凋亡机制中发挥重要作用。
Objective: To investigate the expression and significance of 4 receptors DR4, DR5, DcR1 and DcR2 of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in laryngeal carcinoma. Methods: The expressions of DR4, DR5, DcR1 and DcR2 in 68 cases of laryngeal squamous cell carcinoma and 40 cases of normal laryngeal mucosa were detected by immunohistochemistry. Results: Four receptors of TRAIL were expressed in both laryngeal carcinoma and normal laryngeal mucosa. DR4 and DR5 were highly expressed in laryngeal carcinoma and normal laryngeal mucosa, with no significant difference (all P > 0.05). However, decoy receptors DcR1 and DcR2 were highly expressed in normal laryngeal mucosa and low expression in laryngeal carcinoma (all P <0.05). The higher the degree of differentiation of laryngeal carcinoma, the lower the expression of DR5, the higher the expression of DcR2, the difference was statistically significant (P <0.05). There was no significant difference in the expression of four receptors in all clinical staging cancers (all P> 0.05). Conclusion: The expression of TRAIL receptor is widespread in laryngeal carcinoma, and there are differences in the expression of TRAIL receptor. The role of TRAIL in inhibiting tumor may be related to the different distribution of DcR1 and DcR2 in different tissues. TRAIL gene receptors DR5, DcR2 may play an important role in the mechanism of apoptosis of different pathological stages of laryngeal cancer.